1136PPhase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis

Abstract Background KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3 trial of P or P + chemotherapy (C) vs EXTREME (E) as 1L therapy for R/M HNSCC. At 2nd interim analysis, overall survival (OS) was significantly longer with P than E in patients (pts) with PD-L1 combined positive score...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Tahara, M, Hong, R-L, Wan Ishak, W Z, Yen, C-J, Sriuranpong, V, Takahashi, S, Srimuninnimit, V, Yeh, S-P, Oridate, N, Yang, M-H, Tanaka, K, Nohata, N, Koh, Y, Roy, A, Gumuscu, B, Swaby, R F, Ngamphaiboon, N
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!